IL-1alpha Inhibitors & Biosimilars
2 drugsAbout IL-1alpha
Interleukin-1 alpha (IL-1alpha) is a pro-inflammatory cytokine that mediates the body's immune response. As a signaling protein, it plays a crucial role in inflammation pathways.
IL-1alpha is a valuable drug target in immunology, evidenced by two FDA-approved drugs. However, there is currently no genetic evidence data available linking IL-1alpha to specific diseases.
Two approved drugs, ARCALYST and KINERET, target IL-1alpha, with ARCALYST having 5 indications and KINERET having 4. These drugs are biologics (other) and fusion proteins.
Top IL-1alpha Drugs
Two companies, BIOVITRUM AB and KINIKSA PHARMACEUTICALS (UK), LTD., have approved drugs targeting IL-1alpha.
The presence of only two players suggests a concentrated market, potentially raising entry barriers.
IL-1alpha Drug Modality Landscape
Modalities
Routes of Administration
IL-1alpha requires biologic approaches (biologic (other)), likely due to its structure or location.
Consider exploring small molecule approaches to differentiate from existing biologics.
📈 Modality Evolution
other biologics pioneered IL-1alpha targeting (2001), with fusion proteins entering more recently (2008).
IL-1alpha Clinical Trials 149 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on IL-1alpha. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 39 | 23 | 10 | 6 | 70% |
| Phase 2 | 77 | 49 | 14 | 13 | 78% |
| Phase 3 | 25 | 13 | 4 | 8 | 76% |
| Phase 4 | 8 | 2 | 5 | 1 | 29% |
Top Sponsors
By Modality
IL-1alpha Drug Approval Timeline (2001 - 2008)
The first drug targeting IL-1alpha was approved in 2001 (KINERET), and the most recent in 2008 (ARCALYST).
The 8-year span between approvals suggests a potentially maturing, but not saturated, market.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 84 (8 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on IL-1alpha. A trial counts if an approved drug acting on IL-1alpha is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.